Business Wire

ZCUBE-ZAMBON-RESEARCH

Share
Zcube Launches the 2024 Edition of Open Accelerator, an International Acceleration Program Aimed at Life Sciences Startups with Focus on Women's Health and Femtech

Zcube - Zambon Research Venture announces the fifth edition of Open Accelerator, the international acceleration program for high-potential innovative startups in the field of life sciences. Starting this year, the program will focus on the femtech sector and will feature a new format. The initiative, one of the first internationally in terms of focus and invested capital, invites startups and entrepreneurial ideas aimed at developing products and services to address major medical needs and improve women's health and well-being. The targeted therapeutic areas include gynecology, cardiovascular health, oncology, sexual health, endocrinology, gastroenterology, nutrition, autoimmune disorders, mental health, neurology, reproductive health, and more.

The Call for application will open on Friday, March 8, 2024, on the International Women's Day, and will remain open until June 16. At the end of the selection process, up to 5 startups will be identified to receive an investment of €100,000 each, through a SAFE (Simple Agreement for Future Equity) agreement and will have access to a training and mentoring program delivered by experts in the fields of investments, business development, venture capital, intellectual property, regulatory affairs, and market access.

Startups with the highest potential will also have the opportunity to build a partnership with the Zambon group, accelerating their market access phase and commercial positioning on a global scale.

“We are eager to launch the fifth edition of Open Accelerator; we are excited to discover which companies can bring innovative solutions to change the Life Sciences and women’s health sector. The choice to dedicate the 2024 edition to the femtech sector is deliberate: working in unexplored areas can contribute to creating benefits for the global economy. As highlighted by recent studies, bridging this gender gap is essential” - said Giovanni Magnaghi, President of Zcube and Chief Financial Officer of Zambon – “Since 2016, Open Accelerator has allowed us to offer direct access to capital and expertise to new and promising entrepreneurial ideas, thanks to the collaboration with prominent partners participating in the open innovation ecosystem at our scientific campus, OpenZone, where part of the program is hosted”.

The previous four editions of the program selected 46 startups from 23 countries, 8 of which have received up to €100,000 each in seed investment. The winner of the Distinction Award during the last edition of Open Accelerator comes from the femtech sector: Hyivy Health, a Canadian startup developing a medical device for pelvic floor rehabilitation. Founded in 2019 by Canadian entrepreneur Rachel Bartholomew following a diagnosis of cervical cancer, Hyivy Health aims to improve the standard of care for both patients and physicians through a holistic approach. Bartholomew, CEO of Hyivy Health, commented on the launch of the new edition of Open Accelerator: “It is a turning point for the industry. Open Accelerator is one of the first programs to enter this field with resources and real opportunities for femtech startups on a global level”.

“Open Accelerator values the experience of Zcube and best expresses our vision of Zambon as an open company, where open innovation serves as a lever for cultural and entrepreneurial growth for both us and the entire system” - commented Elena Zambon, President of Zambon and creator of Open Accelerator – “Women's health is a fundamental focus for Zambon and a central issue in international health agendas: supporting these entities and helping them bringing their innovative entrepreneurial ideas to market is an additional effort by our group to innovate cure and care to make patients’ lives better”.

Coordinating Open Accelerator will be a team of professionals experienced in Life Sciences and Venture Capital including Federica Destro, External Innovation & Community manager at Zcube, Vittoria Pavoncello, Technology Scouting & Investment Specialist at Zcube, Michele Gaiotto, CEO of HTH and Advisor to Zcube, and Marco Gullà, Investment Associate at HTH.

For more information about the program, visit www.openaccelerator.it/

For more information about Zcube, visit www.zambon.com/en/innovation/zcube

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240226030549/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Acuity Knowledge Partners Acquires Ascent18.9.2025 09:30:00 CEST | Press release

Acuity Knowledge Partners (Acuity), a leading global provider of bespoke research, data management, analytics and AI solutions to the financial services sector, has announced that it has exchanged on the acquisition of Ascent. The transaction is expected to close on 30th September 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915732380/en/ L-R: Stewart Smythe, Chief Executive Officer, Ascent; Jon O'Donnell, Chief Operating Officer, Acuity Knowledge Partners, and Robert King, Chief Executive Officer, Acuity Knowledge Partners This strategic move significantly expands Acuity's Data and Technology Services (DTS) division and its offering of technology and AI led services and solutions. Ascent, a leading European provider of AI-powered digital transformation services, supports over 170 clients globally, with 550 data, software, and cloud specialists operating across seven European jurisdictions. “Our acquisition of Asc

Shield and PwC UK Forge Strategic Collaboration to Deliver Future-Ready Communications Compliance18.9.2025 08:00:00 CEST | Press release

Collaboration brings together Shield's AI-first platform with PwC's surveillance expertise to deliver measurable compliance outcomes Shield, a leading AI platform for digital communication governance and archiving, today announced a collaboration with PwC UK, one of the world’s most trusted professional services firms. The alliance brings together Shield’s unified, cloud-native solution with PwC’s specialist expertise in communications surveillance delivery, regulatory compliance and complex programme execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917394739/en/ Shield and PwC launch a strategic collaboration to modernize eComms surveillance with AI-driven compliance solutions for financial institutions. The collaboration is designed to support institutions as they modernise their approach to communications monitoring, helping them implement an advanced and proactive risk management approach at scale and with co

Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 202518.9.2025 08:00:00 CEST | Press release

Results of the POSITIVE study assessing the treatment with tildrakizumab showed sustained improvements in skin clearance, psychological well-being, and improved partner quality of life in adults with moderate-to-severe psoriasis over two years.POSITIVE is the first real-world evidence (RWE) study in dermatology to use the WHO-5 Well-Being Index as a primary endpoint, complementing traditional measures of skin disease (PASI, PGA), quality of life (DLQI), with the assessment of psychological well-being, marking a paradigm shift towards holistic management of psoriasis.The POSITIVE study highlights Almirall’s leadership in advancing patient-centred dermatology aligned with the WHO’s health definition and recent resolution on skin diseases.Almirall’s extensive scientific contributions to EADV 2025 include 44 abstracts across key dermatological conditions including atopic dermatitis, psoriasis, actinic keratosis, and hidradenitis suppurativa, and two expert-led symposia. Almirall, S.A. (ALM

Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 07:00:00 CEST | Press release

Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t

Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay18.9.2025 07:00:00 CEST | Press release

Cetaphil's new Skin Activator Hydrating & Firming Line harnesses a proprietary formula, co-created with dermatologists and offering targeted, high-performance skincare designed to improve the appearance of skin affected by dermatoporosis The line’s new Skin Activator technology uses microdosed alpha hydroxy acid (AHA) and encapsulated centella asiatica (CICA) to wake up sleeping surface skin cells To help bring this segment-defining product line to life, Cetaphil is partnering with acclaimed actress, director, and advocate, Mariska Hargitay, a powerful voice in embracing beauty at every stage Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating & Firming line. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of aging, thinning, and fragile skin. As people age, surface

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye